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Abstract
In the future, it may be possible to slow the change in cognition associated with
menopause. First, we must understand the mechanism with which different biological processes
interact in order to slow this decline at the source. An important gene that plays a role in
cognition and aging is the gene for catechol-o-methyltransferase, which is an enzyme that
degrades dopamine in the prefrontal cortex (PFC). Different genotypes cause expression of
varying amounts of the enzyme intended to degrade dopamine in the synapse. When estrogen is
present in the system, transcription of COMT is inhibited. The cognitive effect of the interaction
between lifetime estrogen exposure and COMT was examined in 65 healthy postmenopausal
women. In this study, we tested episodic and working memory, which are associated with PFC
functioning. The subjects were genotyped for the COMT SNP (single nucleotide polymorphism).
An index of lifetime estrogen exposure (ILEE) was created that incorporated reproductive period
(menarche to menopause), total duration of breast-feeding, total time on hormonal therapy, and
time since menopause. We found that in working memory and episodic memory measures, the
effects of ILEE on cognition depended on the COMT genotype. This study showed that
cognition in women with the lower dopaminergic baseline gene, Val/Val, benefitted from
lifetime estrogen exposure. However, cognition in women with the higher baseline dopamine
gene, Met/Met, was negatively affected by lifetime estrogen. Women with the Met/Val gene
were not as impacted by lifetime estrogen. These results suggest that the COMT gene should be
taken into account when considering exogenous estrogen to modulate the decline of cognition
after menopause.

Keywords: estrogen, menopause, COMT, prefrontal cortex, dopamine, cognition
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Introduction
Menopause may be the most important biochemical change in a woman’s life. During
this period the noticeable effects on the brain vary greatly. Some women experience a decline in
memory and other cognitive measures, while others experience very little pathological change.
With the onset of menopause, cognitive decline may be accelerated (Halbreich et al., 1995a).
This acceleration might be due to a deficiency of gonadal hormones, including estrogen. It is
important to understand the underlying neurobiological and genetic mechanisms of menopause
and aging.
Aging causes a decrease in the availability of dopaminergic receptors in the brain, shown
using positron emission tomography (Volkow et al., 1998; Wong et al., 1984). Dopamine is a
neurotransmitter that is involved in cognition and the functioning of the dopaminergic system
changes in normal aging (Braver and Barch, 2002). Dopamine is synthesized in the substantia
nigra and the ventral tegmental regions (VTR) of the brain. From the VTR, it follows the
mesocortical pathway to affect cognitive processes, circulating through the striatum and to the
prefrontal cortex (Malenka et al., 2009).
The concentration of dopamine in the prefrontal cortex (PFC) is controlled by the COMT
gene, which encodes for the COMT enzyme (Lachman et al., 1996). Although the primary site of
the COMT enzymatic interaction with dopamine occurs in the PFC, this enzyme is widely
expressed throughout the brain. The region where the highest dopamine or dopamine metabolite
concentration is the basal ganglia, specifically the lateral putamen, along with high levels found
in the caudate nucleus and the nucleus accumbens (Hall et al., 1994). In regions like these, the
dopamine transporter (DAT) is more likely to control dopamine concentrations since the DAT
has a thousand times greater dopamine affinity then the COMT enzyme (Lewis et al., 2001).
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However, PFC dopamine levels are unaffected by DAT since the DAT is minimally expressed in
this area (Huotari et al., 2002; Sesack et al., 1998). This means the COMT enzyme is the primary
mediator of dopaminergic functioning in the PFC. In addition, mice COMT knockout studies
suggest that dopamine concentration was substantially greater in the PFC compared to the
striatum, where the dopamine transporter mainly controls dopamine functioning (Gogos et al.,
1998). Further research shows that COMT mRNA levels are greater in the PFC than the striatum
(Matsumoto et al., 2003). Therefore, COMT primarily mediates prefrontal cortex dopamine
levels rather than other brain areas, suggesting that COMT controls PFC derived cognitive
processes, including working memory.
This COMT gene has a SNP, which determines COMT enzymatic activity, with the Met
allele having about a quarter of the dopamine degrading enzymatic activity of the Val allele
(Chen et al., 2004). Dopamine impacts cognitive functioning related to the PFC, which includes
working memory, attentional control, and episodic memory (Egan et al., 2001; Schott et al.,
2006). Cognition is impacted differently when different concentrations of dopamine are present.
Specifically, the dopamine receptor produces an inverted-U dose-response, with too little or too
much dopamine impairing working memory (Vijayraghavan et al., 2007). It is important to
understand the factors that impact dopamine concentration.
Human dopamine functioning undergoes dynamic changes through development,
affecting the male and female brains differently (Schulz et al., 2009). In addition, an animal
model of primates suggested that females experience a decline in working memory with the
onset of menopause, independent of age (Hara et al., 2014). Both of these findings imply that the
dopaminergic system is affected by sex hormones, which readily cross the blood-brain barrier.
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Research shows that estrogen’s role in cognition is primarily mediated by the PFC and its
circuitry (Keenan et al., 2001; Krug et al., 2006). Specifically, estrogen has a direct effect on the
COMT gene by inhibiting transcription when estrogen is bound to both response elements on the
promoter of the gene (Weinshilboum, 2006; Xie et al., 1999). Evidence suggests that estradiol
increases dopamine activity (Thompson and Moss, 1994) and dopamine synthesis, release, and
turnover (Becker, 2000). Therefore, the COMT genotype and exposure to estrogen both affect
the amount of dopamine in the brain, which in turn impacts cognition.
One study on premenopausal women found cognitive changes based on the interaction
between COMT and estrogen levels during the menstrual cycle (Jacobs and D'Esposito 2011).
Moreover, this study determined that optimal dopaminergic system functioning occurred in the
Met/Met genotype, but the Val/Val genotype combined with high estrogen during the menstrual
cycle showed the greatest effect on brain functioning during a working memory task. This
finding demonstrates that the changes in hormone levels during the menstrual cycle interact with
the COMT genotype to influence performance and brain functioning during a working memory
task.
Many studies examined the cognitive influence of exogenous estrogen use during or after
menopause, each with varying results (Carlson et al., 2001; Lethaby et al., 2008; Maki, 2005;
Ryan et al., 2009). There are several theories for these inconsistencies. One is that a “critical
window” of estrogen exposure during menopause increases neuroprotection, and different ages
of hormone therapy (HT) may be the reason for variation in the results. Another theory is that
genetic components in the brain impact the range of cognitive results from HT. Lastly, lifetime
estrogen exposure might modulate the effects of HT through menopause. In order to test the
lifetime estrogen theory, studies have explored cognitive changes associated with lifetime
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estrogen exposure, but these results are varied as well (Low et al., 2005; Tierney et al., 2013).
Tierney et al. (2013) found that the reproductive period (between menarche and menopause)
length was related to better delayed visual memory, immediate and delayed verbal memory, and
working memory. On the other hand, Low et al. (2005) determined that the reproductive period
length had no detectable effect on cognition. These studies had not taken into account the COMT
genotype, which may be one reason for the varying results. No one has studied the cognitive
effects of lifetime estrogen with the COMT genotype in postmenopausal women.
Studies often used different markers to identify cumulative estrogen exposure. Several
well-researched factors cause changes in estrogen levels throughout a woman’s life. Exogenous
gonadal steroid use through hormonal contraceptives directly increases estrogen levels. The
duration and age of use of exogenous gonadal steroids could have different effects on
postmenopausal cognition. There are also many endogenous factors that influence hormones.
The duration in a woman’s life when she is reproductive, marked by age at menarche and age at
menopause, influences serum estrogen levels (Geerlings et al., 2001). Pregnancies increase shortterm estrogen levels because the placenta synthesizes and releases estrogen into the body (Siiteri
and MacDonald, 1966). Levels of estrogen are also influenced by interruptions in pregnancies,
whether they are spontaneous abortions (Coulam and Stern, 1994) or induced abortions (Daling
et al., 1996). The Body Mass Index (BMI) of an individual also increases estrogen in the body
(Lukanova et al., 2004). The duration of breast-feeding postpones ovulation due to inhibition of
FSH stimulation in the ovary, and has been shown to depress plasma estrogen levels (Bonnar et
al., 1975).
Rather than examining these lifetime estrogen factors individually, it has been shown that
combining multiple markers into one index increases analytical power and makes results more
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apparent (Smith et al., 1999). Smith et al. (1999) combined several estrogen markers into a
simple Index of Estrogen Exposure (IEE). Factors with clear effects on estrogen were used in
this index. The IEE excluded most reproduction factors because although pregnancy
considerably increases short-term estrogen levels, the long-term implications are more
complicated. Research suggests that parous women experience a gradual decrease in estradiol
level with age during the follicular phase until menopause (Dorgan et al., 1995). Conversely,
follicular phase estradiol levels increase with age in nulliparous women prior to menopause. To
construct the IEE, Smith et al. (1999) standardized the data, then added time on postmenopausal
estrogen therapy, age at menopause, nulliparity, and postmenopausal weight. Age at menarche
and time since menopause were subtracted. This study found that the IEE was most strongly
correlated with global cognitive functioning and verbal attention. No individual estrogen marker
was related to cognition.
Another study used the IEE based on Smith et al. (1999) but included breast-feeding as a
factor that decreased estrogen (Hesson, 2012). They called this index the Index of Cumulative
Estrogen Exposure (ICEE). No significant relationship was found between ICEE and
retrospective memory, but the data suggested prospective memory was positively correlated with
ICEE. In the current study, two indexes of estrogen exposure were used: one that measured every
variable recorded in the questionnaire (TLEE), and another based on the research of Smith et al.
(1999) and Hesson (2012), using only markers that clearly increased estrogen (ILEE). The main
difference between these two created indexes is that the TLEE includes total duration pregnant
and hormonal contraceptives, while the ILEE takes into account years since menopause onset.
The current study examined the interaction between the lifetime estrogen exposure in
postmenopausal women and functioning of the dopamine system in the brain. The purpose of
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this study was to examine how lifetime estrogen exposure interacted with the COMT gene to
affect cognition after menopause, which no other study has examined. Depending on how the
cognitive performance of women with different genotypes is affected by lifetime estrogen, there
may be different hormonal treatments or lifestyle choices suggested in the future. It was
hypothesized that a longer period of exposure to estrogen had a greater effect on cognition in
women with lower dopaminergic functioning, the Val/Val genotype of COMT, more than
women with higher dopamine functioning, with Val/Met and Met/Met genotypes.

Methods
Participants
Women were recruited by calling past research subjects of the Clinical Neuroscience
Research Unit (CNRU) in the Department of Psychiatry and by posting advertisements around
the community. These participants were recruited from the community, and the sample was not
biased based on estrogen use. Once a potential participant called or answered the phone, these
women were told about the study, and then answered questions about medical history during a
telephone screening. Inclusion criteria were an age of 60 to 70, postmenopausal, and healthy.
Women were excluded if they were current smokers, currently taking any medications that
affected the central nervous system, such as anti-depressants, anti-anxiety medications,
antihistamines, or medications altering the dopamine system. Medical history exclusions
included diabetes, heart disease, cancer, chronic obstructive pulmonary disease, depression,
anxiety, and a medical history of loss of consciousness for more than ten minutes due to head
trauma. If a potential participant passed an initial telephone screening regarding age, medication
use, disease history, and menopause history she was scheduled at the University of Vermont
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Clinical Research Center (CRC) for one three-hour study visit. Once the participant arrived,
authorization and consent forms were signed. Each woman provided a DNA sample, completed
cognitive and behavioral screening tests, completed a questionnaire to disclose health
information, answered questions about lifetime estrogen exposure, performed cognitive tasks to
examine working memory and episodic memory, and filled out a series of questionnaires about
subjective cognitive complaints. Details about each of these procedures are below
Cognitive Impairment Screening Tests
All subjects completed a set of initial cognitive status screening questionnaires: Mini
Mental State Exam (MMSE) (Folstein et al., 1975), Dementia Rating Scale (DRS) (Jurica et al.
2001), and Brief Cognitive Rating Scale (BCRS) (Reisberg and Ferris, 1988) which lead to the
Global Deterioration Score (GDS) (Reisberg et al., 1982). On both the DRS and MMSE, a higher
score is related to better global cognitive functioning. Subjects were required to have a score
equal to or greater than 26 on the MMSE, and a DRS score equal to or greater than 123. On the
GDS and BCRS, a higher score was related to a greater amount of cognitive impairment. On the
GDS, a score of 1 or 2 was required for eligibility.
Behavioral Screening
A series of behavioral screening questionnaires was used. This included a modified
version of the Structured Clinical Interview for DSM-IV-TR (SCID) (First et al. 2001), which
screened for current and past depression, current manic disorder, and current dysthymia. In
addition, the Beck Depression Inventory (BDI-II) screened for current depression (Beck et al.
1996). In order to be considered depressed, a score higher than 9 on the BDI was used, along
with an assessment of current major depressive disorder on the SCID. If a subject endorsed
current depression on the SCID, her data were not included in analyses. None of the subjects in
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the present study endorsed current depression, and thus were not ruled out due to the SCID. The
Beck Anxiety Inventory (BAI) was used as a screen for anxiety (Beck et al., 1988). Subjects
were disqualified from all analyses if a score above 15 was calculated from the BAI. One subject
scored greater than 15 and her data were removed from the analysis. We used the Menopause
Symptom Checklist to review the severity of menopausal symptoms the subjects experienced in
the past month. This questionnaire was created by Newhouse and Sargent (2002), modeled after
the Sherwin Menopause Index (Sherwin, 1991). Another questionnaire used for behavioral
screening was the Pittsburg Quality Sleep Index (PQSI), which determined quality of sleep in the
past month (Buysse et al., 1989).
Subjective Cognitive Complaints
Each woman filled out a series of questionnaires used to determine subjective cognitive
complaints of subjects, the Cognitive Complaint Index (CCI). This battery included Memory
Assessment Questionnaire (Pfeffer et al., 1982), Memory-Self Rating Questionnaire (Squire et
al., 1979), Informant questionnaire on cognitive decline in the elderly (Jorm et al., 1994), and ten
questions about mild cognitive impairment (Rabin et al., 2007). More subjective cognitive
complaints had shown to be related to increased neurodegeneration (Saykin et al., 2006). These
subjective cognitive complaints were not related to objective cognitive complaints, but were still
related to brain functioning.
Cognitive Tasks
Working Memory – N-back Test
The N-back Test was used as a measure of verbal working memory. In this task, the
subject viewed a string of consonant letters (except L, W, and Y), one every 3 seconds. Four
conditions were presented: 0-back, 1-back, 2-back and 3-back. In each of the 1-back, 2-back, and
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3-back conditions, the task was to decide whether the letter currently presented matched the
letter that has been presented 1, 2, or 3-back in the sequence. The subjects were asked to press
the “match” button when the letter on the screen matched the letter for the certain conditions, and
the “mismatch” button for every other letter. In the 0-back condition, the subject was given a
target letter and she made a “match” response when that target appeared. This condition required
attention and focus, but no working memory. In the one-back condition, the goal was to press the
match button when a letter matched the letter that appeared just prior (the letter appearing one
item back). In the two-back condition, the match occurred when a letter was identical to the
letter two items back. In the three-back condition, a match occurred when a letter was identical to
the letter that appeared three items back. Participants were given two trial rounds of each
condition before performing the full N-back task used in this study. Accuracy measures and
reaction times were automatically recorded for each trial. Dumas et al. (2010) have shown that
estrogen in postmenopausal women affected prefrontal brain regions involved in this task.
Episodic Memory Buschke Selective Reminding Test (SRT)
The Buschke SRT was used to measure episodic memory (Buschke and Fuld, 1974). The
SRT is a multi-trial verbal list-learning task allowing the examination of acquisition, encoding,
and retrieval. This standard test offers measures of storage into and retrieval from memory. For this
task, a list of 16 unrelated words was read aloud to the subject. The subject recalled as many words
as possible. Then, the person administering the task would selectively remind the subject of the
words that she did not recall, and asked her to try to recall the list of 16 words again. There were
eight trials in this task. In addition, there was one trail that was administered about 20 to 30 minutes
after the end of the eighth trial. The total recall was the total amount of words the subject recalled
from all eight trials. Consistency occurred when the subject remembered a word in succession for
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two trials. Intrusions were words the subject recalled not on the specified list. Recall failure
occurred when the subject failed to remember a word on two consecutive trials. Totals among these
variables in all trials were added to give total recall, total consistency, total recall failure, total
intrusions, and delayed recall.
Indices of Estrogen Exposure Questionnaire
Each woman answered questions about lifetime hormone exposure divided into 4
sections: menstrual cycle history, motherhood, menopause, and history of HT (Lord et al., 2009).
The menstrual cycle history inquired about age at menarche, amenorrhea, and contraceptive
hormone use. The motherhood section asked about pregnancies, miscarriages, and breastfeeding. The next section included age at menopause and whether it was natural or surgically
induced. The last section was about hormonal therapy type, duration, and age. Lord et al. (2009)
found this self-report estrogen use questionnaire to be reliable. The data collected from the
questionnaire was converted into hormone history indices.
Index of Lifetime Exposure to Estrogen (ILEE)
All estrogen exposure markers were converted to years. Duration of breast-feeding was
added across children for each woman, resulting in the total duration of breast-feeding. Time
since menopause was calculated as current age minus age at menopause (age at last period).
Adding all durations of hormonal therapy used for menopause created total hormonal therapy
(total HT). To form the index, factors causing an increase in estrogen were added (age at
menopause, total HT), and the markers that lead to a decrease in estrogen were subtracted (time
since menopause, age at menarche, and total duration of breast-feeding). This index was based
off of Smith et al. (1999) and Hesson (2012). However, unlike their models, I did not include
postmenopausal weight (Smith) or BMI (Hesson) because this factor was an instantaneous
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measurement rather than constant throughout life. I also did not include nulliparity in this index
because the short-term and long-term effects of pregnancy on estrogen levels have shown to be
contrasting (Dorgan et al., 1995).
Total Lifetime Estrogen Exposure (TLEE)
TLEE was an index that included all the variables on the questionnaire. Pregnancies were
converted to years, and then added into the total duration pregnancy for each woman. Hormonal
contraceptives were converted to years, creating the total hormonal contraceptives measure. The
markers that cause an increase in estrogen were added (total duration pregnancy, total duration
hormonal contraceptive, total duration hormonal replacement therapy, reproductive period from
menarche to menopause) and one factor that is related to low estrogen (duration of breastfeeding).
Genotype
Subjects provided a buccal DNA sample. A clinical research nurse from the University of
Vermont Medical Center, specifically the Clinical Research Center (CRC), ran a buccal cheek
swab across the inside of each woman’s cheek. Then, the sample was stored in a -20°F freezer
until all the samples were collected. DNA extraction and single nucleotide polymorphism (SNP)
analysis were conducted at the Vermont Cancer Center DNA Analysis lab. COMT val158met
polymorphism was determined using TaqmanTM Genotyping Master Mix. The PCR products
were analyzed using Applied Biosystems Prism 7900HT Sequence Detection System, version
SDS 2.4. Each woman was either Met/Met if there were two adenosine nucleotides at this loci,
Met/Val if both alleles were present, or Val/Val if there were only guanine nucleotides.

ESTROGEN AND COMT IN POSTMENOPAUSAL WOMEN

14

Vital Signs and BMI
During each study day, a clinical research nurse from the CRC obtained height, weight,
and the vital signs: respiratory rate, blood pressure, temperature, and pulse rate from the subject.
Based on the height and weight, we calculated BMI for each subject.
Data Analysis
The COMT genotype was used as a grouping variable. In addition, a median split was
used to separate women into high and low estrogen groups based on ILEE and TLEE separately.
To test my hypotheses about lifetime estrogen exposure, COMT genotype, and cognition after
menopause, I used a 2(ILEE: high and low) x 3(COMT genotype: Val/Val, Met/Val, Met/Met)
ANOVA. ILEE group and genotype were between subjects factors. The ILEE hormone exposure
variable was also used a continuous variable, changing the analyses into a regression model.
Since the indices I used have many variable components, I also explored the correlations
between cognition and the different markers for estrogen exposure individually. Many studies
showed varying results in the literature of estrogen factors that were related to cognition.

Results
Participants
A total of 67 subjects were enrolled. Two subjects were excluded from analyses. One was
ineligible because she was unable to finish the study day due to mental fatigue. The other
reported above the allotted BAI score for anxiety. Out of the 65 analyzed subjects, 19 were
Val/Val, 36 were Val/Met, and 10 were Met/Met. Table 1 shows the means of age, education,
and BMI for the different genotypes.
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Subjects ranged from 60 to 70 years old, with a mean age of 64.3 years (SD 3.1). These
women had a mean education of 16.6 years (SD 1.9) and a mean BMI of 26.9 (SD 5.7). The
average age at menarche was 12.7 years (SD 1.3) and the average age at menopause was 52.1
years (SD 3.3). In this study, 72.3% of women were parous, and, including pregnancy
interruptions, like abortions and miscarriages, the mean total duration of pregnancy was 1.6 years
(SD 1.1). Out of all the women analyzed, 61.5% breast-fed at least one child. 83.1% of the
women reported using hormonal contraceptives, and the mean total duration of birth control for
all women was 5.43 years (SD 6.4). In addition, 44.6% of the women used postmenopausal
hormonal therapy throughout menopause, and among those, the mean duration of HT was 4.7
years (SD 5.1). Table 2 shows the averages for the estrogen markers measured. The means of the
screening tests (Table 3), behavioral data (Table 4), and cognitive tasks (Table 5) are reported.
Working Memory (N-Back)
2-Back Hits, ILEE Grouping Variable, and COMT Genotype
The 2-Back condition measures working memory. In this condition, women were asked
to indicate if the current letter matched the letter that appeared two items before.
There was an interaction between COMT genotype and the ILEE groups for the 2-back
condition of the N-back working memory task (F(2,59)=3.80, p=0.028). There was also a main
effect of COMT genotype (F(2,59)=3.66, p=.032). There was no main effect of the ILEE
grouping variable (p=.23) (Table 6). Overall, the means showed the Val/Val group performed
better than the Met/Val and the Met/Met groups. The post hoc t-test showed there was no
significant difference between the Val/Val and the Met/Val groups (t(53)=1.97, p= 0.054) or
between the Val/Val and Met/Met groups (t(27)=1.52, p=0.140). For the Val/Val group, the
means showed that women in the low ILEE group performed worse than the women in the
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Val/Val who were in the high estrogen ILEE group, but the post hoc t-tests were not significant
(t(17)=1.53, p=.143). For the Met/Val group there was no difference between the high and low
ILEE group (t(34)=0.197, p=.845). For the Met/Met group, there was a significant difference
between the high and low ILEE group, with the low estrogen group performing better than the
high estrogen (t(8)=2.64, p=.030). However, there were only two women in the high estrogen
condition (see Table 7 and Figure 1).
3-Back Hits, ILEE Grouping Variable, and COMT Genotype
The 3-back condition is a more difficult task than the 2-back, as it requires holding more
information in working memory.
There was no COMT genotype and ILEE group interaction for the 3-back condition
(p=.326). However, there was a main effect of ILEE group (F(2,59)=4.93, p=0.030) and a main
effect of COMT genotype for the 3-back of the N-back working memory test (F(2,59)=4.00,
p=0.024) (Table 6). Overall the Met/Met group performed worse than the Met/Val (t(44)=2.06,
p=.045) . The means showed that the Met/Met performed better than the Val/Val, but not
significantly (t(27)=1.56, p=.130). There was no significant difference between the Met/Val and
Val/Val groups (t(53)=0.084, p=.934). The means display the low estrogen performed better
than the high estrogen group. There were no significant differences between high and low
estrogen groups (t(63)=1.34, p=.186) (see Table 8 and Figure 2).
Episodic memory (SRT)
Total Recall, ILEE Grouping Variable and COMT Genotype
There was an interaction between COMT genotype and the ILEE groups for the total
recall condition of the Buschke SRT for episodic memory (F(2,59)=3.67, p=0.03). There were
no main effects of the COMT genotype (p=0.12) or the ILEE groups (p=0.82) (Table 6). For the
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Val/Val women, the low ILEE group performed worse than the high ILEE group, but not
significantly (t(17)=1.85, p=0.081). For the Val/Met women, high and low estrogen group
performance did not differ much (t(34)=0.270, p=0.789). For the Met/Met group, the means
indicated that low estrogen exposure group performed better than the high estrogen group, but
not significantly (t(8)=2.088, p=0.070). (See Table 9 and Figure 3).
SRT Total Recall Failure, ILEE Grouping Variable, and COMT Genotype
There was an interaction between COMT genotype and the ILEE for the total recall
failure condition of the Buschke SRT for episodic memory (F(2,59)=7.22, p=0.002). There were
no main effects of the COMT genotype (p=0.13) or the ILEE groups (p=0.42) (Table 6). For the
Val/Val women, the means showed that the low ILEE group had significantly more recall
failures, denoting worse performance, than the high ILEE group (t(17)=2.26, p=0.037). For the
Val/Met women, the high estrogen group and the low estrogen group had similar performance
(t(34)=0.666, p=0.510). For the Met/Met group, the high estrogen exposure group had
significantly more recall failures than the low estrogen group (t(8)=4.40, p=0.002) (see Table 10
and Figure 4).
Individual estrogen components correlate with cognition
When I used the ILEE as a continuous variable instead of grouping variable there was no
correlation between estrogen exposure and working memory, episodic memory, or cognitive
complaints. However, there was a correlation between global cognitive functioning measured
with the DRS and continuous ILEE (r= .330, p=.007). Higher global cognitive functioning was
related to greater lifetime estrogen exposure.
The ILEE factor has many components. Separately, some of these markers were related
to cognition. Understanding which factors were related to cognition alone is very important and
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many studies research individual components rather than making indices. Thus, I examined
correlations between the individual hormone measures and the cognitive measures.
Global Cognitive Functioning
There was a correlation between global cognitive functioning measured with the DRS
and the amount of time since menopause (r= -.368, p= .003). This means that less time since
menopause was related to higher global cognitive functioning.
Subjective Cognitive Complaints
There was a correlation between the subjective cognitive complaints reported with the
MFQ and the total duration pregnant (r=.416, p=.001). Thus, greater subjective cognitive
complaints were related to a longer total duration pregnant.
Episodic Memory
There was a correlation between number of total intrusions, a measure of inaccurate
recall, on the Buschke SRT and the total pregnancy duration (r=.357, p=.004). Therefore, more
intrusions were related to longer total duration pregnant.
Age was an important factor among some variables of the Buschke test. Age was
correlated with the Buschke task total recall (r= -.272, p=.029). This means that increased age
was related to performing worse on the total recall on the Buschke SRT. Also, age was correlated
to total consistency on the Buschke SRT (r= -.276, p= .026). Increasing age was related to worse
performance on consistency of the Buschke SRT. Following this pattern, total recall failure on
the Buschke SRT was correlated with age (r= .248, p= .046). Increasing age was related to more
recall failures.
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Working Memory
On the N-back task, 0-back hits were positively correlated with total menopausal
hormone therapy duration (r=.286, p=021). This means that a longer duration of hormone
therapy through menopause was related to better performance on the 0-back task. However, 0back hits were negatively correlated with the duration of hormonal contraceptive earlier in life
(r= -.321, p=.009). Therefore, the longer the duration of hormonal contraceptives was related to a
worse 0-back performance.
For the 1-back condition on the N-back task, hits were negatively correlated with TLEE
(r= -.29, p=.02). Higher total estrogen exposure, considering all the markers, was related to poor
performance on the 1-back condition.
However, performance was close to ceiling for the 0-back and 1-back conditions.

Discussion
As hypothesized, the effects of lifetime estrogen exposure on cognition were modulated
by COMT genotype, since a greater amount of lifetime estrogen exposure benefitted the lower
baseline dopamine genotype (Val/Val), but was detrimental to women with the higher baseline
dopamine gene (Met/Met). Overall, the means for working memory, as measured by 2-back hits,
and the episodic memory measures, SRT total recall and SRT recall failure, suggested that the
effects of ILEE on cognition depended on the COMT genotype. This study showed that
cognition in Val/Val women was positively affected by lifetime estrogen exposure. However,
cognition in women with the higher baseline dopamine gene, Met/Met, was more negatively
affected by higher lifetime estrogen exposure. Women with the Met/Val gene displayed
cognitive performance that seemed unaffected by lifetime estrogen. This is probably because in
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the PFC, dopamine was most beneficial at an intermediate concentration, but more detrimental as
it reached the extremes.
Interactions between genotype and estrogen affecting cognition were also found in an
fMRI study of premenopausal women (Jacobs and D'Esposito, 2011). In the Jacobs and
D'Esposito (2011) study, the effects of estrogen depended on the baseline of dopamine
determined by genetics. The fMRI showed similar results to my study because Jacobs and
D'Esposito found Met/Met women performed best under low estrogen conditions and decreased
performance under high estrogen conditions. In addition, the Val/Val subjects had impaired
cognition when estrogen was low, but improved performance with higher estrogen.
With the increased working memory load in the 3-back condition, the interaction of
COMT and ILEE group on cognition no longer occurred. However, main effects of both
genotype and ILEE were present. The ILEE main effect for the 3-back condition had means that
displayed the low ILEE group performed better than the high ILEE group. The genotype main
effect showed the Met/Met genotype did worse than both the Val/Val and the Val/Met. In
addition, the greatest performance difference between high and low ILEE occurred in the
Met/Met genotype, with the high ILEE Met/Met group performing worse than all other groups.
When considering the main effects of ILEE and genotype separately, it appeared the women with
higher dopamine performed worse. This might be because studies have suggested more
dopamine correlated with increased anxiety, which is related to a decreased attention control that
may have affected performance on the difficult 3-back condition (Eysenck et al., 2007). In
addition, research suggested that anxiety is a characteristic of the high baseline dopamine allele,
Met/Met (Olsson et al., 2005). An fMRI study suggested that due to the difficulty level, the 3back condition caused more disengagement, and the 2-back was likely a better predictor of
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working memory because most subjects can remain focused and with continual effort (Ayaz et
al., 2012). This disengagement is likely seen in higher dopamine individuals more because of
higher anxiety rates. Therefore, the 3-back condition might not be as predictive of cognitive
performance as the 2-back condition.
In addition to the results of the results from the ANOVA, there was a correlation between
ILEE as a continuous variable and global cognitive functioning. This is a replication of the
finding by Smith et al. (1999), suggesting that increased global cognitive functioning is related to
women with greater lifetime estrogen exposure. However, ILEE as a continuous variable was not
correlated to working memory or episodic memory. When grouped by a median split into high
and low ILEE, there were effects on working memory and episodic memory. Further research is
necessary in order to understand these relationships.
Limitations
One limitation in this study is that the Met/Met high estrogen group had a sample size of
two women. Both of these women performed similarly in episodic memory and working memory
tasks so there was at least no outlier in their performance. However, the relationship between
cognition, estrogen, and COMT genotype found in this small sample size may be unreliable. A
larger sample size of Met/Met women is needed to confirm that these results are not due to
chance. The total sample size is a limitation to this study. With a larger sample, statistical power
would be greater. Additionally, the women in this study were well educated, Caucasian, and all
from the Vermont area. This sample probably does not accurately represent the population of
postmenopausal women. With a larger sample size and greater variance through the sample, our
results would be more reliable.
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A second limitation was that the estrogen questionnaire was retrospective. The data were
collected solely by subjective memory, and thus may not represent the true levels of lifetime
estrogen exposure. However, prior studies have shown that the duration of hormone therapy
through menopause and type of menopause (surgery, natural) were highly correlated with
medical record findings of these events (Colditz et al., 1987; MacLennan et al., 2006). Other
factors were found to be reliable, but not necessarily accurate in retrospective events because not
compared to medical records. These included age at menarche, number of pregnancies, duration
of hormonal contraceptive, and duration of HT use (Lord et al., 2009). In addition, doses of
hormonal contraception and HT were not included since these factors were often unable to be
reported. In addition, diet and lifetime BMI may be important factors when considering lifetime
estrogen exposure, but since this study is retrospective, this information may be inaccurate or
unreliable. Collecting data from both the women and medical records would reduce the chance
of inaccuracies in the estrogen exposure data.
Future Directions
This study examined working memory, which has primarily function of the frontal lobes
(Goldman-Rakic et al., 2004; Kane and Engle, 2002), and episodic memory, which is primarily a
function of the hippocampus (Burgess et al., 2002). The N-back task has been shown in fMRI
studies to reliably activate the bilateral frontal lobes but also activates bilateral parietal lobes and
bilateral cerebellum (Cohen et al., 1997). The Buschke is a measure of episodic memory, which
primarily requires hippocampal functioning for good performance (Buschke and Fuld, 1974;
Rosen et al., 2003). However, the frontal lobes are also involved in episodic memory
performance (Wheeler et al., 1995). A future study might attempt to use cognitive tasks that
require smaller or more prescribed brain networks for their performance. However, the current
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tasks were chosen because of the reliable nature of the brain networks that they require for good
performance. Some potential examples might be a test of spatial navigation to specifically
involve the hippocampus or a category test or decision-making tasks (Shepard et al., 1961) to
examine frontal lobe function further.
Conclusions
Many studies show that lifetime estrogen exposure increased cognition later in life (Heys
et al., 2011; Li et al., 2014; Ryan et al., 2009; Silverman et al., 2011), although results varied
(Low et al., 2005). Studies reported that estrogen modulates cognition by inducing dendritic
spine formation of the CA1 region of the hippocampus in a temporary fashion (Woolley and
McEwen, 1992). However, this finding does not support why lifetime estrogen would impact
cognition in the PFC. One study explored the effects of estradiol on the PFC in female monkeys
and suggested that that long term exposure to estradiol (17β) with cyclical peaks may be the most
effective way to cause dendritic spine generation, turnover, and consolidation (Hao et al., 2006).
Therefore, it is possible that lifetime estrogen, particularly the reproductive period from
menarche to menopause, induces a permanent change in dendritic spines.
There are a number of potential mechanisms that may explain how lifetime estrogen
affects cognition after menopause. Estrogen influences multiple neurotransmitters, including
cholinergic (Bora et al., 2005; Luine, 1985), serotonergic (Halbreich et al., 1995b), adrenergic
(Sar and Stumpf, 1981), and dopaminergic (Roy et al., 1990) systems. In addition, estrogen
affects the brain in a number of ways. Estrogen is an endocrine sex hormone produced in the
ovaries, which also functions in the central nervous system. Research has shown that estrogen
can also be locally synthesized in the brain from cholesterol and act in as a paracrine hormone
(Do Rego et al., 2009). This locally synthesized estrogen can regulate synaptic plasticity (Kretz
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et al., 2004), as well as neurogenesis in the dentate gyrus (Tanapat et al., 2005). Estrogen can
also be produced by neurons or astrocytes, or from circulating testosterone by aromatase. The
aromatase level in the PFC was found to be significantly higher in females than males (Wei et
al., 2014). Research shows that inhibited aromatase is related to memory impairment in females
(Phillips et al., 2011). In an animal model, the brain-derived estrogen was a more direct and
significant risk factor for cognitive decline by Aβ plaque formation than circulating estrogen
(Yue et al., 2005). Therefore, more research is needed to determine the multiple effects of
estrogen in the brain and how these are changed after menopause.
Another hypothesis of circulating estrogen is that telomerase plays a role in the
endocrine-related cognitive decline. Longer telomeres are related to lower rates of cognitive
decline and lower rates of cardiovascular disease (Miller et al., 2003). Estrogen can reduce
oxidative stress and inflammation (Xing et al., 2009), which may cause a quicker decrease of
telomere length (Correia-Melo et al., 2014; von Zglinicki, 2002). Overall, it has been shown that
endogenous estrogen exposure, measured as reproductive years, protects against telomere
shortening, and associated with higher cognition in older women (Lin et al., 2011).
Another possible mechanism by which lifetime estrogen impacts cognition after
menopause is potentially by increasing cognitive reserve. Cognitive reserve is the idea that
across the lifespan, higher education, participation in social or mentally stimulating activities,
and complexity of occupation increases resistance to dementia (Harrison et al., 2015). Some
studies show that women with higher levels of estrogen have better cognition (Sherwin, 1997).
Perhaps compared to women with low levels of lifetime estrogen, women with higher lifetime
estrogen continually displayed a better cognition, building better cognitive functioning leading
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into older age. However, the neurobiological mechanisms underlying cognitive reserve remain
to be determined.
The results of the current study suggest that women with a specific genotype would
benefit more from estrogen therapy during menopause than others. In the future it may be
possible to use a different form of medications to alleviate cognitive decline, such as a COMT
inhibitor for Val/Val women. This may be more advantageous because higher levels of estrogen
are related to an elevated risk of breast cancer (Colditz et al., 1993). In addition, some women
have risk factors that are complications for exogenous estrogen due to medical contraindications
or family history (Shifren and Schiff, 2010). More research with larger sample sizes about the
interaction of lifetime estrogen, cognition, and genotype is needed before any treatment
recommendations are made. However, the current data are a first step towards understanding
these relationships.
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Table 1
Demographic data Means (standard deviation) by genotype
Genotype

Age

Education BMI

N

38
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Val/Val

64.4 (3.4)

17.3 (2.0)

24.7 (3.3)

19

Val/Met

64.2 (3.1)

16.3 (1.6)

27.7 (6.5)

36

Met/Met

64.1 (3.0)

16.2 (2.6)

28.6 (5.7)

10

Total

64.2 (3.1)

16.6 (1.9)

26.9 (5.7)

65

Table 2
Demographic and Lifetime Hormonal Exposure Means and
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Standard Deviation
Estrogen Marker

Mean

SD

ILEE

30.1

6.9

TLEE

49.3

7.2

Age Menarche

12.7

1.2

Horm. Contraceptive Duration

5.4

6.4

Pregnancy Duration

1.6

1.1

Breast-Feeding Total Duration

.88

0.94

Age at Menonopause

52.1

3.2

HT Duration

2.0

4.0

Years Since Menopause

12.1

4.6

Note. ILEE=Index of Lifetime Estrogen Exposure; TLEE=Total
Lifetime Estrogen Exposure; Horm.= hormonal

Table 3
Screening Questionnaire Means and Standard Deviation
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Form

Mean

SD

MMSE

28.7

1.1

DRS

141

2.5

SCID- Past

0.2

0.4

BCRS

8.5

0.8

GDS

1.3

0.5

Table 4
Behavioral Data Means and Standard Deviation

41

ESTROGEN AND COMT IN POSTMENOPAUSAL WOMEN
Form

Mean

SD

BDI

1.3

2.1

BAI

2.6

3.1

Study Symptom

13.4

12.5

PQSI

4.1

3.2

Table 5
Cognitive Tasks/Complaints Mean and Standard Deviation
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Measure

Mean

SD

SRT Total Recall

82.2

13.8

SRT Total Consistency

46.8

18.4

SRT Total Recall Failure

11.7

8.4

SRT Total Intrusion

1.5

2.2

SRT Delayed Recall

10.4

3.4

0 Back Hits

0.991

0.027

0-Back FA

0.002

0.007

1-Back Hits

0.93

0.134

1-Back FA

0.022

0.041

2-Back Hits

0.876

0.125

2-Back FA

0.102

0.063

3-Back Hits

0.731

0.155

3-Back FA

0.079

0.063

MFQ

5.29

1.05

Table 6
Results of Univariate Analyses of COMT genotype, ILEE, and the interaction between

43

ESTROGEN AND COMT IN POSTMENOPAUSAL WOMEN

44

COMT genotype and ILEE on working memory and episodic memory.
Dependent Variable

Source

2-Back Hits

3-Back Hits

SRT Total Recall

SRT Total Recall Failure

DF

F

Sig.

Geno

2

3.66*

0.03

ILEE

1

1.45

0.23

Geno*ILEE

2

3.80*

0.03

Geno

2

4.00*

0.02

ILEE

1

4.93*

0.03

Geno*ILEE

2

1.14

0.33

Geno

2

2.23

0.12

ILEE

1

0.05

0.82

Geno*ILEE

2

3.67*

0.03

Geno

2

2.11

0.13

ILEE

1

0.67

0.42

Geno*ILEE

2

7.22**

0.002

Note. *p < .05. **p< .01.

Table 7
Proportion 2-Back Hits Correct Split by COMT Genotype and ILEE Group
Geno

ILEE

Mean

SD

N
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Val/Val

Met/Val

Met/Met

Total

45

Low

0.881

0.156

9

High

0.964

0.069

10

Total

0.925

0.123

19

Low

0.862

0.128

15

High

0.854

0.118

21

Total

0.857

0.121

36

Low

0.893

0.108

8

High

0.679

0.051

2

Total

0.850

0.132

10

Low

0.875

0.128

32

High

0.877

0.124

33

Total

0.876

0.125

65

Table 8
Proportion 3-Back Hits Correct and Standard Deviation Split by COMT
Genotype and ILEE Group
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Geno

ILEE

Mean

SD

N

Val/Val

Low

0.754

0.160

9

High

0.736

0.196

10

Total

0.744

0.175

19

Low

0.795

0.132

15

High

0.714

0.141

21

Total

0.748

0.141

36

Low

0.688

0.114

8

High

0.464

0.152

2

Total

0.643

0.147

10

Low

0.757

0.139

32

High

0.706

0.167

33

Total

0.731

0.155

65

Met/Val

Met/Met

Total

Table 9
SRT Total Recall Means and Standard Deviation Split by Genotype and Estrogen
Group
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Geno

ILEE

Mean

SD

N

Val/Val

Low

70.7

19.8

9

High

84.5

12.3

10

Total

77.9

17.3

19

Low

84.0

7.1

15

High

85.1

14.5

21

Total

84.6

11.8

36

Low

85.4

11.6

8

High

67.5

2.1

2

Total

81.8

12.7

10

Low

80.6

13.9

32

High

83.8

13.8

33

Total

82.2

13.9

65

Met/Val

Met/Met

Total

Table 10
SRT Total Recall Failure Means and Standard Deviation Split by Genotype and
Estrogen Group
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Geno

ILEE

Mean

SD

N

Val/Val

Low

19.0

13.3

9

High

8.8

5.0

10

Total

13.6

10.9

19

Low

9.7

5.6

15

High

11.3

8.0

21

Total

10.7

7.1

36

Low

8.8

4.5

8

High

23.5

0.7

2

Total

11.7

7.4

10

Low

12.1

9.2

32

High

11.3

7.6

33

Total

11.7

8.4

65

Met/Val

Met/Met

Total

Table 11
Correlations

ILEE
TLEE
Age

TLEE

0.41*
-0.26

0.24

Age

T Dur
Preg

Horm.
Cont.

HT

Time
Since
Meno

SRT
Intrusi
on

0Back
Hits

1Back
Hits

MFQ
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Figure Legends

Figure 1. Mean proportion correct and standard error of 2-Back Hits split by genotype and Index
of Estrogen Exposure (ILEE) group. There was an interaction between COMT genotype and the
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ILEE groups for this task (F(2,59)=3.80, p=0.028). There was also a main effect of COMT
genotype (F(2,59)=3.66, p=.032). For the Met/Met group, there was a significant difference
between the high and low estrogen group with the low ILEE group performing better than the
high ILEE group (t(8)=2.64, p=.030). *p< 0.05.
Figure 2. Mean proportion correct and standard error of 3-Back Hits Split by Genotype and
Index of Estrogen Exposure (ILEE) group. There was a main effect of ILEE group
(F(2,59)=4.93, p=0.030) and a main effect of COMT genotype for the 3-back of the N-back
working memory test (F(2,59)=4.00, p=0.024). Overall the Met/Met group performed worse than
the Met/Val (t(44)=2.06, p=.045). *p< 0.05.
Figure 3. Mean and standard error of SRT Total Recall Split by Genotype and Index of Estrogen
Exposure (ILEE) group. There was an interaction between COMT genotype and the ILEE groups
for the total recall condition of the Buschke SRT for episodic memory (F(2,59)=3.67, p=0.03).
Figure 4. Mean and standard error of Total SRT Recall Failure Split by Genotype and Index of
Estrogen Exposure (ILEE) group. There was an interaction between COMT genotype and the
ILEE for the total recall failure condition of the Buschke SRT for episodic memory
(F(2,59)=7.22, p=0.002). For the Val/Val women, the low ILEE group had more recall failures,
indicating worse performance, than the high ILEE group (t(17)=2.26, p=0.037). For the Met/Met
group, the high estrogen exposure group had a greater amount of recall failures than the low
estrogen group (t(8)=4.40, p=0.002). *p< 0.05.
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